The purpose of the present invention is to provide an evaluation method kit for evaluating the risk of onset of diffuse alveolar damage due to such factors as anticancer drug administration. The purpose of the present invention is also to provide a method for evaluating the risk of onset of side effects in anticancer drug treatment. An evaluation method and evaluation kit for evaluating the risk of onset of diffuse alveolar damage, including detecting gene polymorphism present in the MUC4 gene. A method for evaluating the risk of onset of side effect in anticancer drug treatment, including detecting gene polymorphism present in the MUC4 gene of a patient scheduled for anticancer drug administration.